CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?

CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All th...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhade, Amol, Van Wambeke, Simon, Gyawali, Bishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470169/
https://www.ncbi.nlm.nih.gov/pubmed/36200010
http://dx.doi.org/10.3332/ecancer.2022.ed124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470169/
https://www.ncbi.nlm.nih.gov/pubmed/36200010
http://dx.doi.org/10.3332/ecancer.2022.ed124

Ejemplares similares